Newborn screening for spinal muscular atrophy allows for earlier diagnosis in preterm infants, leading to earlier use of disease-modifying therapies, in the presymptomatic stage, and better long ...

—Newborn screening for spinal muscular atrophy allows for earlier diagnosis in preterm infants, leading to earlier use of disease-modifying therapies, in the presymptomatic stage, and better ...

New research suggests previous assumptions about the pathogenesis of spinal muscular atrophy (SMA) are inadequate. Patients with severe infantile spinal muscular atrophy (SMA) have significant ...

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...

The mutation that causes Spinal Muscular Atrophy (SMA) can be detected in a ... panel suggest that if the cost of testing every infant is not outweighed by the benefit of early detection, then ...

Considering taking supplements to treat spinal muscular atrophy? Below is a list of common natural remedies used to treat or reduce the symptoms of spinal muscular atrophy. Follow the links to ...

An 11-month-old baby with spinal muscular atrophy (SMA) needs a Rs 14.2 crore life-saving gene therapy. The Supreme Court ...

The Phase 3 STEER trial enrolled more than 100 children with SMA type 2, ages 2-17, who were able to sit, but hadn't walked ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma ...

Spinal muscular atrophy (SMA) is a devastating ... SMA, though a rare disease, is the leading genetic cause of infant death. The severity of the condition varies across a spectrum of types.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.